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Some toxins and drugs can trigger lasting neuroprotective mechanisms that enable neurons 
to resist a subsequent severe insult. This “pharmacological preconditioning” has far-reaching 
implications for conditions in which blood flow to the brain is interrupted. We have previously 
shown that in vitro preconditioning with the AMPA receptor antagonist GYKI 52466 induces 
tolerance to kainic acid (KA) toxicity in hippocampus.  This effect persists well after washout of the 
drug and may be mediated via inverse agonism of G-protein coupled receptors (GPCRs). Given 
the amplifying nature of metabotropic modulation, we hypothesized that GYKI 52466 may be 
effective in reducing seizure severity at doses well below those normally associated with adverse 
side effects. Here we report that pharmacological preconditioning with low-dose GYKI imparts 
a significant protection against KA-induced seizures in vivo. GYKI (3 mg/kg, s.c.), 90–180 min 
prior to high-dose KA, markedly reduced seizure scores, virtually abolished all level 3 and level 
4 seizures, and completely suppressed KA-induced hippocampal c-FOS expression. In addition, 
preconditioned animals exhibited significant reductions in high frequency/high amplitude spiking 
and ECoG power in the delta, theta, alpha, and beta bands during KA. Adverse behaviors often 
associated with higher doses of GYKI were not evident during preconditioning. The fact that 
GYKI is effective at doses well-below, and at pre-administration intervals well-beyond previous 
studies, suggests that a classical blockade of ionotropic AMPA receptors does not underlie 
anticonvulsant effects. Low-dose GYKI preconditioning may represent a novel, prophylactic 
strategy for neuroprotection in a field almost completely devoid of effective pharmaceuticals.
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and Sutula, 2002). It is well-established that neuroprotectants are 
often ineffective when administration is significantly delayed, as 
is often the case in human stroke (Chauhan et al., 2003). Ideal 
neuroprotectants would be those that trigger endogenous neuro-
protective pathways when administered to at-risk patients before 
an ischemic insult occurs, and could be of real benefit in cases of 
cardiac or brain surgery in which global or focal CNS ischemia is 
likely. A number of studies in recent years have shown that CNS 
neurons do in fact possess inducible neuroprotective mechanisms 
and can be preconditioned in a variety of ways to resist hypoxic 
or excitotoxic insults. In addition, evidence indicates that precon-
ditioning procedures can impart a rapid tolerance to subsequent 
seizurogenic or excitotoxic insults, which may be observed within 
minutes of preconditioning.
In the course of assessing pharmacological preconditioning 
mechanisms, we found that in vitro preconditioning with GYKI 
52466 induces a lasting tolerance versus kainic acid (KA) toxicity 
in hippocampal CA1, and that this effect may be metabotropic in 
nature (Hesp et al., 2004). In those studies we found that a number 
of ionotropic AMPA and KA antagonists (including GYKI 52466) 
also acted as inverse agonists of G-protein coupled receptor (GPCR) 
function, significantly reducing constitutive GTPase activity in hip-
pocampal membranes from young but not aged rats. In addition, 
in rat hippocampal CA1, low concentrations of GYKI 52466, and 
NBQX-induced tolerance to the adverse electrophysiological effects 
of high-dose KA, even after the antagonists had been washed from 
IntroductIon
GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-
 5 H-2,3-benzodiazepine hydrochloride) is a non-competitive AMPA 
receptor negative allosteric modulator (Donevan and Rogawski, 
1993; Zorumski et al., 1993) which has been examined in a number 
of seizure models including audiogenic seizures (Smith et al., 1991; 
De Sarro et al., 1998a,b, 2003; Szabados et al., 2001), maximal electro-
shock seizures (Donevan et al., 1994; Borowicz et al., 1995; Szabados 
et al., 2001; Barton et al., 2003; De Sarro et al., 2003; Gressens et al., 
2005), amygdala-kindled seizures (Borowicz et al., 2001), and chem-
oconvulsant-induced seizures (Donevan et al., 1994; De Sarro et al., 
2003). Most of these studies found GYKI 52466 to be an effective 
anticonvulsant, exhibiting ED50′s of approximately 10–25 mg/kg 
when administered 15–30 min prior to seizure induction. GYKI 
52466’s effects have been shown to last from 60 to 90 min (De Sarro 
et al., 1998a, 2003), with plasma concentrations peaking within 
15 min and dropping to less than 5% of peak levels within 90 min 
of i.p injection (De Sarro et al., 1998b). Unfortunately, debilitating 
motor and cognitive side effects have been routinely documented at 
doses as low as 10–15 mg/kg (Donevan et al., 1994; Borowicz et al., 
1995, 2001). Given the short duration of action and magnitude of 
adverse effects seen at effective doses, the therapeutic utility of GYKI 
52466 has remained limited.
Seizures and epilepsy often arise following stroke or traumatic 
brain injury (Karhunen et al., 2007). At the same time, uncontrolled 
seizure activity can lead to CNS damage (Sloviter, 1987; Pitkänen Frontiers in Neuroscience  |  Neuropharmacology    August 2010  | Volume 4  | Article 54  |  2
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seizure behaviors leading to level 5 clonic–tonic convulsions (CTC; 
for more detail, see Hesp et al., 2007). If an animal exhibited two 
periods of prolonged CTC, the animal was immediately sacrificed 
and all subsequent observation periods were recorded as level 5. In 
the ECoG study, the entire experiment was videotaped and coded 
for subsequent blind behavioral analysis.
Cumulative seizure scores were defined as the sum of the highest 
scores observed during each 1-min period during the 2 h follow-
ing KA injection. In addition, average scores during each 1-min 
observation period were summed and assessed for all drug condi-
tions. Cumulative averages were found to be tightly correlated to 
cumulative maxima, and consequently, only cumulative maxima 
are reported here. Furthermore, the total number of wet dog shakes 
(WDS), level 3, and level 4 behaviors were discretely quantified 
over the 2-h observation period. At the conclusion of behavioral 
observations, rats were rendered unconscious by CO2 and decapi-
tated. Brains were then removed, frozen on dry ice and stored for 
subsequent immunohistochemical staining.
dual channel dIgItal transmItter ImplantatIon
Carprofen 5 mg/kg and strepcin 250 IU s.c. were administered to 
animals 30 min prior to surgery and for 3 days post-operatively. 
Animals were anesthetized with ketamine hydrochloride 75 mg/
kg, Domitor® (medetomidine) 0.4 mg/kg, and atropine 0.05 mg/
kg. Body temperature was maintained at 37ºC throughout the pro-
cedure. A 2-cm transverse incision was made in the skin over the 
lower abdomen and a two-channel digital transmitter (Telemetry 
Research, Auckland, NZ) was implanted within a small subcuta-
neous pocket. An ECG reference lead was sutured to the xiphoid 
process and other leads were subcutaneously tunneled to the rostral 
thorax. A small incision exposed the tracheal muscle, and the cardiac 
recording lead was formed into a U shape, then positioned close 
to the right atrium for ECG recording. The two ECoG electrode 
leads were tunneled subcutaneously to a point just posterior to the 
foramen magnum. The rat was placed into a stereotaxic frame, an 
incision made lengthwise along the skull, and the skin retracted. 
the slice preparation. Taken together, our findings suggest that tol-
erance is triggered by a selective reduction in constitutive GPCR 
activity, and this metabotropic neuroprotective mechanism is lost in 
aged hippocampus (Hesp et al., 2004). Given the lasting and ampli-
fying nature of metabotropic modulation, we hypothesized that 
GYKI 52466 may be effective in reducing seizure severity at doses 
well below those normally associated with adverse side effects. In 
the present study we examined the anticonvulsant effects of GYKI 
52466 versus KA-induced seizures across a range of low doses and 




All procedures were approved by the University of Otago Animal 
Ethics Committee and conducted in accordance with the New 
Zealand Animal Welfare Act. Male Sprague–Dawley rats, 2–3 months 
old and weighing 200–280 g, were obtained from the University 
of Otago Hercus-Taieri animal colony and housed for at least one 
week in the departmental holding facility on a 12-h light–dark 
cycle, with free access to food and water.
drugs and reagents
Kainic acid and GYKI 52466 hydrochloride were obtained from 
Tocris Bioscience (UK), dissolved in sterile saline (with small pH 
adjustment as necessary) and administered at rates of 1 mL/kg body 
weight. Immunohistochemistry reagents were sourced as described 
below. All other chemicals and reagents were acquired from BDH 
Chemicals (Poole, England).
BehavIoral oBservatIon and analysIs
Prior to behavioral observation animals were allowed to acclimate 
for 30 min in a custom-made PerspexTM observation chamber 
(Aburn Glass, Dunedin, NZ). For the initial parametric analysis 
of GYKI preconditioning, rats were injected with GYKI 52466 
(0.3, 1, or 3 mg/kg or saline vehicle; s.c.) 10, 90, or 180 min prior 
to a single injection of KA (10 mg/kg; a dose which reliably pro-
duces clonic–tonic convulsions within 120 min of administration). 
For the subsequent ECoG study, rats were injected with saline or 
GYKI 52466 (1 mg/kg or 3 mg/kg, s.c.) at selected time points (10, 
90, 180 min) prior to a single injection of KA (10 mg/kg, s.c.). 
Treatment groups and Ns are shown in Table 1.
Immediately following KA injection, animals were returned to 
the observation chamber and behaviors recorded in a 1-min-on and 
1-min-off cycle for 2 h, with all behaviors during each observation 
period coded and logged to a laptop computer, using a spreadsheet 
based program developed in our lab. To ensure that observations 
were recorded systematically, when a particular behavior (e.g., sleep-
ing, walking, etc.) was continuously expressed, observations were 
only logged once every 15 s. Discrete changes in behavioral state 
were additionally logged as they occurred. Behaviors were rated 
using a seizure scale previously employed in our lab (Hesp et al., 
2007; Sawant et al., 2010) in which level 0 consists of normal rest-
ing or exploratory behaviors, level 1 – discomfort behaviors, level 
2 – stereotypical behaviors confined to the head and neck region, 
level 3 – moderate seizure behaviors associated with stereotypical 
movements of the limbs or trunk, and level 4 – severe generalized 
Table 1 | Drug treatment conditions.
Preconditioning    Challenge  N 
paradigm
Experiment 1 – Parametric analyses
Saline, 1 mL/kg  90-min pre-challenge  Saline (1 mL/kg)  8
Saline, 1 mL/kg  90-min pre-challenge  KA (10 mg/kg)  8
GYKI 52466, 0.3 mg/kg  90-min pre-challenge  KA (10 mg/kg)  4
GYKI 52466, 1 mg/kg  90-min pre-challenge  KA (10 mg/kg)  4
GYKI 52466, 3 mg/kg  10-min pre-challenge  KA (10 mg/kg)  4
GYKI 52466, 3 mg/kg  90-min pre-challenge  KA (10 mg/kg)  5
GYKI 52466, 3 mg/kg  180-min pre-challenge  KA (10 mg/kg)  4
Experiment 2 – ECoG analyses
Saline, 1 mL/kg  90-min pre-challenge  KA (10 mg/kg)  7
GYKI 52466, 1 mg/kg  90-min pre-challenge  KA (10 mg/kg)  5
GYKI 52466, 1 mg/kg  180-min pre-challenge  KA (10 mg/kg)  5
GYKI 52466, 3 mg/kg  10-min pre-challenge  KA (10 mg/kg)  4
GYKI 52466, 3 mg/kg  90-min pre-challenge  KA (10 mg/kg)  6
GYKI 52466, 3 mg/kg  180-min pre-challenge  KA (10 mg/kg)  5www.frontiersin.org  August 2010  | Volume 4  | Article 54  |  3
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Seizure-related c-Fos immunoreactivity was observed in all sub-
regions of the hippocampus. As expression was strongest in the 
granule cells of the dentate gyrus (DG), only DG granule cell layer 
c-Fos expression is reported here. Immunoreactivity was assessed 
relative to non-seizure (saline only) controls using blind observer 
scoring (Kapoor et al., 2004; Clarkson et al., 2005). Micrographs 
of sections from experimental conditions were paired with micro-
graphs of control tissue processed on the same slide. Five blind 
observers were presented with pairs and asked to compare the right 
image to the left image (control and experimental micrographs 
were randomly alternated between left and right). Observers rated 
the relative degree of c-Fos immunoreactivity (right vs. left) on 
a scale of −3 to +3, where +3 is more immunoreactive, −3 is less 
immunoreactive and a score of 0 represents no difference.
statIstIcs
For  behavioral  analysis  and  immunohistochemical  grading, 
Kruskal–Wallis ANOVAs with Dunn’s post hoc tests were conducted 
for each data set. For post hoc purposes, the saline/saline control 
and saline/KA seizure groups were compared either to the 0.3, 1, 
and 3 mg/kg 90 min GYKI 52466 pre-treatment groups, or to the 
3 mg/kg 10, 90, or 180 min GYKI 524466 pre-treatment groups, 
to differentiate dose- and time-dependent effects. p < 0.05 was 
considered to be a significant difference. A two-tailed Spearman’s 
non-parametric correlation was used to determine the relationship 
between c-Fos staining and cumulative maximum seizure scores. 
For analysis of electrocortigraphic data, HF/HA spiking data was 
transformed  using  a  natural  log,  and  analyzed  using  one  way 
ANOVA with Bonferroni post hoc. ECoG power spectral density 
data was found to violate assumptions of equal variance, so was 
likewise transformed using a natural log.
results
seIzure InductIon followIng salIne or gyKI precondItIonIng
Behavioral analysis was undertaken for low-dose GYKI precondi-
tioning, and all periods were compared to 60-min saline precon-
ditioning controls. The pre-treatment dose for GYKI 52466 was 
set at 3 mg/kg or lower, as previous studies have shown that these 
doses cause no adverse behavioral effects (Rorick-Kehn et al., 2005). 
Our observations confirmed that low-dose GYKI 52466 does not 
adversely affect animal behaviors (data not shown); during GYKI 
preconditioning rats exhibited normal behaviors such as explor-
ing, grooming and periodic resting, and these behaviors were not 
significantly different from those behaviors observed during the 
baseline acclimation period.
Following saline preconditioning, rats were injected with either 
saline (saline controls) or KA (10 mg/kg, s.c.; seizure controls). In 
saline controls, a second injection of saline caused no observable 
changes in animal behaviors. In contrast, in saline preconditioned 
seizure controls, high-dose KA produced seizures which steadily 
increased during the 2-h observation period (cumulative seizure 
scores: seizure controls vs saline controls; p < 0.01; Figure 1).
When GYKI 52466 (3 mg/kg) was administered only 10 min 
prior to KA, cumulative seizure scores were comparable to those 
seen in saline preconditioned rats (N.S.). The same was seen when 
GYKI 52466 (3 mg/kg) was administered 180 min prior to KA. 
However, when GYKI (3 mg/kg) was administered 90 min prior to 
Two stainless steel anchoring screws were drilled bilaterally into the 
skull. The stereotaxic co-ordinates for recording the electrode were 
5.2 mm posterior to bregma, 5 mm left of the midline, and 2-mm 
depth (from skull surface). The reference electrode was placed 
5 mm posterior to bregma, 2 mm right of the midline and 1-mm 
depth. Electrodes were inserted slowly to reduce tissue damage, 
and were immediately fixed in place using superglue to prevent 
movement. The leads were secured by suturing to muscle on the 
neck, so that the vigorous body movements commonly occurring 
during seizures would not displace the electrodes. Finally, electrodes 
and screws were fixed to the skull using cranioplastic cement and 
the scalp sutured. Animals were allowed 8–10 days to recover from 
implantation surgery before experimentation.
ecog recordIngs and spectral analysIs
Data were recorded with a Powerlab 2/25 signal conditioner and 
Chart 6 analysis software (AD Instruments, Sydney). ECoG activity 
was acquired continuously for the duration of the experiment at 
2 kHz, with receivers set to 0.1 Hz high pass and 1000 Hz low pass fil-
ters. Fast Fourier transformation was used to quantify the following 
frequency bands: delta (1.25–4.50 Hz), theta (4.75–6.75 Hz), alpha 
(7.00–12.50 Hz), beta (12.75–35 Hz), and gamma (35.5–100 Hz). 
Simultaneous ECG recording allowed the removal of high frequency/
high amplitude movement artifacts which invariably occurred dur-
ing (WDS). ECoG recordings were examined in 10-min periods. 
These sampling periods were analyzed by dividing them into half 
overlapping half-second epochs, using a weighted Cosine bell win-
dow. Power spectral density (PSD) for each period was calculated as 
the sum of all epochs. Baseline PSD for each animal was determined 
as the mean of the three 10-min periods during acclimatization. 
PSD values for subsequent periods were expressed as a percentage 
of baseline and averaged within treatment groups. High frequency/
high amplitude (HF/HA) spiking was also quantified as a measure of 
seizure activity. These were defined as spikes of at least three times 
the average spike amplitude during baseline.
c-fos ImmunohIstochemIstry
A large body of research indicates that c-Fos protein expression 
increases with seizure severity, peaks in hippocampus 1–2 h fol-
lowing a seizure, and is particularly robust in the dentate gyrus. 
Immunohistochemical c-Fos staining was carried out using the 
protocol described by Sundquist and Nisenbaum (2005), with 
slightly  longer  incubations  to  ensure  strong  immunoreactiv-
ity. Frozen brains were cryosectioned (10 μ), mounted on poly-
l-lysine coated slides and post-fixed in 4% paraformaldehyde. 
Endogenous peroxidases were quenched with 0.3% H2O2 (Merck) 
and non-specific antibody binding was blocked by incubating 
sections in 0.015% normal goat serum (Vectorlabs, Burlingame, 
CA, USA). Sections were incubated over night in 1:2000 rabbit 
anti-c-Fos primary antibody (Calbiochem, San Diego, CA, USA) 
prior to incubation with biotinylated goat anti-rabbit secondary 
antibody (Vectorlabs). Antibody binding was visualized using the 
ABC complex (Vectorlabs) and a Sigma FastTM 3,′3 diaminoben-
zidine (DAB) peroxidase substrate tablet set (Sigma Chemicals, St. 
Louis, MO, USA) in distilled H2O. Sections were then dehydrated 
in ascending concentrations of methanol and cleared in xylene 
before coverslipping.Frontiers in Neuroscience  |  Neuropharmacology    August 2010  | Volume 4  | Article 54  |  4
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saline preconditioning, cortical activity was not significantly differ-
ent from that observed during the baseline (acclimation) recording 
period. ECoG traces routinely exhibited extended periods of low 
power activity interrupted by occasional spikes or brief flurries of 
activity associated with exploring and grooming (Figure 4). Following 
the high-dose KA challenge, saline preconditioned animals exhibited 
several minutes of hyperactivity and exploratory behaviors followed 
by a short (approx. 15 min) period of hypoactivity. Within 20 min 
of KA administration, head tremors, mastication, freezing and WDS 
occurred with increasing frequency, and these were associated with 
the appearance of regular high frequency/high amplitude (HF/HA) 
electrical activity in the cortex. High level convulsive seizures (level 3 
KA, animals exhibited a significant reduction in cumulative scores 
in the 2-h period following high-dose KA (p < 0.05). These rats 
only exhibited level 1 and 2 behaviors, and infrequent WDS. Lower 
preconditioning doses of GYKI (0.3 and 1 mg/kg; 90 min pre-
challenge) did not significantly reduce seizure scores (Figure 1).
To further assess differences between rats pre-treated with saline 
or GYKI 52466, the number of WDS (a pronounced level 3 behavior), 
the net occurrence of level 3 or above behaviors, and the net occur-
rence of level 4 behaviors were quantified (Figure 2). GYKI 52466 
(3 mg/kg), 90 min prior to high-dose KA, virtually abolished all level 
3 and level 4 seizures (p < 0.05). GYKI 52466 (3 mg/kg) precondition-
ing 180 min prior to seizure induction also markedly reduced level 4 
behaviors (Figure 2). In contrast, lower doses of GYKI or a shorter 
pre-administration period (10 min) prior to KA, was ineffective.
c-fos ImmunohIstochemIstry
Minimal c-Fos labeling was seen in tissue from saline control rats. 
This tissue was used as a comparison for the estimation of c-Fos 
immunoreactivity in experimental animals. Seizure control rats dis-
played intense c-Fos immunoreactivity in the dentate gyrus of the 
hippocampus. Seizure-induced c-Fos expression was significantly 
attenuated by administration of 3 mg/kg GYKI 52466 90 min prior 
to KA administration (Figure 3A; p < 0.05). Comparable reductions 
in c-Fos immunoreactivity were not evident when seizure animals 
were pre-treated with 1 mg/kg GYKI 52466 given 90 min or 3 mg/
kg GYKI 52466 given 10 or 180 min before KA (Figure 3B). The 
relationship between behavioral measures and c-Fos expression was 
examined using individual data from each animal and revealed a 
positive, significant correlation between cumulative maximum sei-
zure score and c-Fos expression in the dentate gyrus (Figure 3C).
ecog actIvIty durIng pharmacologIcal precondItIonIng and 
seIzure InductIon
Based on results obtained during the parametric analyses described 
above, a second set of experiments were conducted to determine 
whether changes in electrocorticographic activity parallel behavioral 
changes observed following saline and GYKI preconditioning. During 
FIGurE 1 | Cumulative seizure scores following saline or low-dose GYKI 
52466 preconditioning. Histograms show mean ± SEM cumulative seizure 
scores. Labels along the x axis indicate preconditioning paradigm. All groups 
received KA (10 mg/kg) except control animals, which received a second saline 
injection. Scores were calculated from the 2-h monitoring period following KA 
injection. *p < 0.05 vs. Saline, **p < 0.01 vs. Saline.
FIGurE 2 | Net occurrence of wet dog shakes, level 3 and level 4 seizure 
behaviors exhibited following saline or low-dose GYKI 52466 
preconditioning. Histograms show mean ± SEM number of discrete events 
during the 2-h seizure induction period. Labels along the x axis indicate 
preconditioning paradigm.*p < 0.05 vs. saline.www.frontiersin.org  August 2010  | Volume 4  | Article 54  |  5
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work, significant decreases in Level 4 behaviors were observed for sev-
eral treatment groups (Figure 5). The greatest reduction was observed 
for the 3 mg/kg 90 min group which exhibited only 5.3 ± 2.0 discrete 
level 4 seizure behaviors over the entire 2-h observation period (ver-
sus saline controls; 35.7 ± 7.1; p = 0.001; Figure 5). Significant reduc-
tions in level 4 seizure behaviors were also observed in the 3 mg/kg 
180 min group (p = 0.007) and 3 mg/kg 10-min group (p = 0.019). 
The number of HF/HA spikes observed during the 2-h observa-
tion periods were analyzed (Figure 5). Observation of ECoG traces 
showed no evidence of HF/HA spiking during baseline or during 
saline or GYKI preconditioning for any of the animals in either group. 
However, relative to saline, GYKI preconditioned animals exhibited 
reductions in HF/HA spiking during the high-dose KA challenge. 
In particular, HF/HA spiking during KA was markedly reduced in 
the 3 mg/kg GYKI 90 min preconditioning group (1067 ± 324), and 
this reduction was significantly different from that observed in saline 
controls (5553 ± 1114; p = 0.031; Figure 5).
ecog power spectral densIty
Consistent with current and prior behavioral observations, we 
generally observed changes in ECoG signal intensity as early as 
10–15 min, and peak changes from 90 to 120 min following KA 
and 4 behaviors) of variable intensity occurred approximately 40 min 
after KA in saline preconditioned animals (Figures 4 and 5), and in 
all cases were associated with robust increases in ECoG power and 
electrographic spiking. ECoG recording revealed strong seizure activ-
ity during the kainic acid challenge in 100% of saline treated rats.
During  low-dose  GYKI  preconditioning,  animals  exhibited 
ECoGs not significantly different from those obtained during the 
baseline recording period. Following the KA challenge, GYKI treated 
animals exhibited low-level exploratory behaviors that were some-
times interrupted by wet-dog shakes and other level 2 and 3 seizure 
behaviors. These behavioral manifestations were associated with 
moderate increases in ECoG power and generally persisted for less 
than 1 h. Following this, GYKI preconditioned animals settled into 
sleeping and resting behaviors with occasional periods of exploring 
and grooming; ECoG power during this latter period was not dif-
ferent from baseline (Figures 4 and 5). Consistent with our earlier 
observations, the 3 mg/kg 90-min GYKI preconditioning group 
exhibited a small but significant reduction in cumulative seizure 
scores (p = 0.027; data not shown). Non-significant decreases were 
also observed in the 1 mg/kg 180 min, 3 mg/kg 10 min, and 3 mg/kg 
180 min groups. There were no significant differences in the average 
number of level 3 behaviors. However, consistent with our   previous 
FIGurE 3 | Effects of GYKI 52466 preconditioning on KA-induced c-Fos 
expression in the dentate gyrus. (A) Representative micrographs of c-Fos 
immunoreactivity in the dentate gyri of (A1) saline treated controls; (A2) 
KA treated animals that received saline pre-treatment; (A3) KA treated 
animals that received 3 mg/kg GYKI 52466 90 min beforehand. 
(B) Histograms of varying GYKI 52466 dose and pre-treatment period on 
KA-induced c-Fos expression in the dentate gyrus relative to saline controls 
(mean ± SEM; *p <0.05). (C) Spearman’s non-parametric correlation 
between c-Fos immunoreactivity and cumulative maximum seizure 
score; p < 0.05.Frontiers in Neuroscience  |  Neuropharmacology    August 2010  | Volume 4  | Article 54  |  6
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and chemically induced seizures (for an extensive review see De 
Sarro et al., 2005). In most of these studies ED50s ranged from 13 
to 25 mg/kg when the drug was administered 15–30 min prior to 
seizure induction. Worryingly, debilitating motor and cognitive 
effects have been seen at 10–15 mg/kg and most investigators 
have concluded that the “therapeutic utility of GYKI 52466 is 
limited” (Barton et al., 2003; De Sarro et al., 2005; Weiczner 
et al., 2008).
Here, we obtained in vivo evidence that pharmacological pre-
conditioning with low-dose GYKI 52466 is sufficient to impart 
a significant protection against KA-induced seizures. In these 
studies young adult rats were preconditioned with saline or 
GYKI 52466 at doses 5- to 20-fold lower than published ED50s for 
anticonvulsant activity, and seizures were induced 10–180 min 
later. Low-dose GYKI (3 mg/kg, s.c.), 90 min prior to high-dose 
injection (Figure 6). Fast Fourier transform was used to assess 
ECoG power spectral density (PSD) over the entire 2-h recording 
period, and analysis of variance indicated a main effect of drug 
treatment in seizure expression following KA (F = 4.86; p = 0.004); 
GYKI preconditioned animals exhibited significant reductions in 
ECoG PSD across frequency bands relative to saline controls and 
these reductions were most pronounced at 3 mg/kg either 90 or 
180 min prior to seizure induction (delta: p < 0.01; theta: p = 0.003; 
alpha: p < 0.01; beta: p < 0.01; gamma: N.S; Figure 6).
dIscussIon
antIconvulsant and neuroprotectIve actIons of gyKI 52466
GYKI 52466 has been assessed as a potential anticonvulsant in a 
number of animal models of seizure, including audiogenic sei-
zures, maximal electroshock seizures, amygdala-kindled seizures, 
FIGurE 4 | Typical ECoG traces from rats preconditioned with (A) saline 
or (B) GYKI 52466 (3 mg/kg 90 min) followed by KA (10 mg/kg) seizure 
challenge. (A1, A2): Example traces from two saline preconditioned rats. 
(A3) Magnification of boxed section in (A2). (B1, B2) Example traces from 
two rats preconditioned with GYKI (3 mg/kg), 90 min prior to KA 
administration. (B3) Magnification of boxed section in (B2). White arrows 
indicate time of preconditioning injection. Filled arrows indicate time of KA 
injection. Complete traces are 2-h duration; magnified traces are 2 min 
duration. Traces adjusted vertically for visual comparison as signal strength 
varied between experiments.www.frontiersin.org  August 2010  | Volume 4  | Article 54  |  7
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KA, markedly reduced cumulative seizure scores, virtually abol-
ished all level 3 and level 4 seizures, and completely suppressed 
KA-induced hippocampal c-FOS expression. In the present study 
we further assessed functional CNS protection by low-dose 
GYKI preconditioning using telemetric electrocorticographic 
(ECoG) recording coupled with behavioral analysis and found 
that preconditioned animals exhibited significant reductions 
in high frequency/high amplitude spiking and ECoG power in 
the delta, theta, alpha, and beta bands during high-dose KA. 
This anticonvulsant effect was not observed when GYKI was 
administered 10 or 180 min before seizure induction or at lower 
doses (≤1 mg/kg). In addition, adverse behaviors (loss of motor 
control, sedation, etc.) were not evident during the precondi-
tioning period, and our observation that both HF/HA spiking 
and c-FOS expression were dramatically reduced by GYKI pre-
conditioning confirms that the reduction of high level (motor) 
seizure behaviors were not simply due to GYKI-induced paraly-
sis or sedation. Although we cannot directly confirm that GYKI 
52466 suppresses seizures via KA-sensitive GPCRs, the fact that 
the compound was effective at doses well-below, and at time 
FIGurE 5 | Histograms of net occurrence of level 4 seizure behaviors and 
high frequency/high amplitude (HF/HA) electrographic spikes during the 
2-h seizure induction period following saline or GYKI 52466 
preconditioning. Totals were averaged within treatment groups 
(mean ± SEM; *p < 0.05, **p < 0.01, ***p = 0.001).
FIGurE 6 | Average power spectral density (PSD) of ECoG recordings 
during seizure induction for saline (dark bars) and GYKI 52466 (3 mg/kg 
90 min; light bars) preconditioned rats. Histograms show average PSD 
(mean ± SEM) for each 10-min epoch during the 2-h KA challenge. 
Preconditioning effects were analyzed separately for each frequency band 
(Delta (1.25–4.5 Hz); Theta (4.75–6.75 Hz); Alpha (7 .00–12.5 Hz); Beta 
(12.75–35 Hz); Gamma (35.5–100 Hz). **p < 0.01.Frontiers in Neuroscience  |  Neuropharmacology    August 2010  | Volume 4  | Article 54  |  8
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in the CNS even after it has been cleared from the plasma. However 
it remains clear that low-dose GYKI preconditioning offers clinical 
efficacy without dosing at toxic levels. Taken together, our find-
ings support the possibility of a long-lasting preconditioning effect 
mediated by a metabotropic mechanism, and suggest that GYKI 
52466 and related compounds may be used prophylactically to 
protect the CNS.
While the exact location and function of the G-protein that 
GYKI 52466 may influence is not known, the findings of the current 
study coupled with prior data (Hesp et al.; 2004) are compatible 
with the proposal that excitotoxic preconditioning is mediated via 
inverse agonism of a metabotropic pathway. This as yet unidenti-
fied receptor may bind KA, DOM, and GYKI 52466 in a similar 
manner, lowering the constitutive activity of a G-protein complex 
leading to downstream effects that protect the cell from subsequent 
insult. The G-protein complex may be a separate membrane bound 
GPCR or may be linked to a currently known (but misunderstood) 
ionotropic receptor (Lerma, 2006). Indeed, recent studies have chal-
lenged the dogma that non-NMDA glutamate receptors are purely 
ionotropic in action, suggesting that KA and AMPA receptor com-
plexes play metabotropic roles in regulating neuronal activity. It has 
been demonstrated that KA receptors can have a G-protein linked 
function (Cunha et al., 1999; Melyan et al., 2002; Fernandes et al., 
2009; Segerstråle et al., 2010) that may involve protein kinase C 
(PKC; Rodriguez-Moreno et al., 2000; Kurkinen et al., 2001; Jung 
et al., 2005), protein kinase A- (PKA; Rodriguez-Moreno and Sihra, 
2004) or mitogen-activated protein kinase (MAPK; DeCoster et al., 
1998). AMPA receptors have also been linked to second messenger 
cascades (Wang and Durkin, 1995; Perkinton et al., 1999). Our data 
suggest that GYKI 52466 may be equally efficacious via metabo-
tropic receptors (relative to its classical effects as a negative allos-
teric modulator of the AMPA receptor), with second messenger 
amplification accounting for the effects of GYKI at the unusually 
low doses and extended time points used in this study.
The long-lasting anticonvulsant efficacy of low-dose GYKI pre-
conditioning seen here fits well with existing literature regarding 
early and delayed windows of preconditioning protection. A large 
number of studies in recent years have shown that CNS neurons do 
in fact possess inducible neuroprotective mechanisms, and can be 
preconditioned in a variety of ways to resist hypoxic or excitotoxic 
insults. In general most preconditioning paradigms have involved 
moderate to severe insults many hours to days apart, and in many 
cases resulted in lasting neuroprotection (Pohle and Rauca, 1994; 
Best et al., 1996; El Bahh et al., 1997; Najm et al., 1998; Lere et al., 
2002; Tandon et al., 2002; Chang et al., 2005; Wang et al., 2005). 
However, a growing body of evidence indicates that preconditioning 
procedures can impart a rapid tolerance to subsequent excitotoxic 
insults which may be observed within minutes of conditioning. For 
example, early work showed that anoxic preconditioning or brief 
exposure to depolarizing agents imparts a robust, Ca2+-dependent 
tolerance to subsequent anoxic depolarization (Centeno et al., 1999; 
Perez-Pinzon et al., 1999), and evidence of rapid “cross condition-
ing” in vitro has also emerged (Schurr et al., 2001; Youssef et al., 
2001). Importantly, in studies of in vitro ischemic preconditioning, 
an “early window” of   neuroprotection has been identified which 
may involve rapid shifts in glutamate and GABA release (Dave et al., 
2005; for review, see Perez-Pinzon, 2007).
intervals well-beyond previous studies, suggests that a classical 
blockade of ionotropic AMPA receptors does not underlie the 
anticonvulsant effect.
a novel, metaBotropIc mechanIsm of actIon?
GYKI 54266 has been classed as a selective non-competitive allos-
teric AMPA receptor antagonist. GYKI binding presumably causes 
a conformational change in the receptor that inhibits the binding 
of glutamate and related agonists such as KA. As such, negative 
allosteric modulation has been assumed to account for GYKI’s 
anticonvulsant activity versus excitotoxicity and seizures (Donevan 
et al., 1994; De Sarro et al., 2003). However prior work by our 
group suggests that this compound may also act via a metabotropic 
mechanism to prevent seizures (Hesp et al., 2004).
Using the hippocampus as a model system, we have shown that 
low dose preconditioning with either kainate or the neurotoxin 
domoic acid (Kerr et al., 2002; Hesp et al., 2004, 2007; Sawant 
et al., 2007, 2008, 2010) induces tolerance against the hyperexcita-
tory actions of much higher doses of these toxins, both in vitro 
and in vivo. Interestingly, these effects are generally less robust in 
aged animals. Given the lasting nature of the tolerance effect, we 
examined G-protein coupled receptor function. Results of these 
studies (Hesp et al., 2004) suggest that tolerance induction likely 
occurs via recently described KA-sensitive G-protein-linked recep-
tors (Rozas et al., 2003; Lerma, 2006; Rodriguez-Moreno and Sihra, 
2007). We found that a number of ionotropic KA receptor agonists 
(KA, DOM, ATPA, and SYM-2081) significantly reduce constitutive 
GTPase activity in hippocampal membranes from young but not 
aged rats. Furthermore, in the course of searching for other ligands 
which reliably induce tolerance to excitotoxins we found, quite unex-
pectedly, that a number of ionotropic AMPA and KA antagonists 
(such as CNQX, NBQX, GYKI 52466, NS-102, and GAMS) also act 
as strong inverse agonists of G-protein receptor function in young 
but not aged rats, and some of these act as strong preconditioning 
agents in vitro (Hesp et al., 2004). Notably, in young rat hippocampal 
CA1, low concentrations of the AMPA/KA blockers GYKI 52466 and 
NBQX-induced tolerance to high-dose KA administered well after 
the antagonists had been washed from the slice preparation. These 
findings suggest that tolerance is triggered by a selective reduction 
in constitutive KA-sensitive GPCR activity, and this metabotropic 
neuroprotective mechanism may be lost in aged hippocampus.
In the present study we found that low-dose GYKI 52466, admin-
istered 90–180 min prior to systemic administration of kainic acid, 
produces significant reductions in behavioral, electrographic, and 
immunohistological indices of seizures. Our parametric analysis 
indicates that preconditioning protection is optimal at 3 mg/kg, 
90 min prior to seizure induction. No prior studies have shown 
a protective effect with GYKI 52466 at doses as low as 3 mg/kg 
(Donevan et al., 1994; Borowicz et al., 2001; De Sarro et al., 2003). 
Of particular interest is the fact that low-dose GYKI 52466 markedly 
reduced KA-induced seizures when injected 90 min prior to KA. 
This lasting anticonvulsant efficacy is difficult to explain in terms 
of classical AMPA receptor antagonism by GYKI. As an ionotropic 
AMPA receptor antagonist, 3 mg/kg GYKI 52466 should have little 
effect 90 min after administration when very little GYKI is remain-
ing in the plasma (De Sarro et al., 1998b). We cannot rule out the 
possibility that GYKI crosses the blood–brain barrier and lingers www.frontiersin.org  August 2010  | Volume 4  | Article 54  |  9
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